Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Melanoma 2Carcinosarcoma 2Bile Duct Neoplasms 2Advanced Solid Tumours 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour Refractory to Conventional Treatment 1Salivary Gland Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasms × ceralasertib × Clear all
NCT05941897 2026-03-05

LOTOS

AstraZeneca

Phase 2 Active not recruiting
39 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

NCT02630199 2022-06-15

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Samsung Medical Center

Phase 1 Completed
65 enrolled
Tumor-Agnostic

Neoplasms

NCT03669601 2021-06-04

ATRiUM

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Unknown
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡